projects

About
Partnerships
Product Pipeline
Enabling Technologies
Resources
Contact

We envision a time when cancer
is no longer a problem

InterVenn is the cutting-edge leader for glycoprotein analysis, biomarker research, liquid-biopsy assay development, and new drug target discovery. Our unique platform uses deep learning to automate analysis of a rich field of biomarkers so diverse and complex that it would be otherwise inaccessible.

For Investors

InterVenn not only works closely with leading pharma, biotech, and diagnostic companies during every phase of development, but is also planning commercial launch of its own clinical service offerings.

For Partners

We work closely with leading pharma, biotech, and diagnostic companies during every phase of development, augmenting their systems and processes with the unique InterVenn platform.

For Physicians

Our goal has always been to help patients and their physicians by providing assays that outperform currently available ones, with a focus on cancer.

First Of Its Kind

InterVenn is building unique, powerful liquid-biopsy solutions by leveraging the rich diversity of protein glycosylation*.

Glycosylation is the process of attaching sugar molecules to a variety of biological materials such as proteins, lipids and even RNA. Glycosylation is essential for normal cell and organ functions, but alterations have been associated with a variety of diseases including cancer.

Artificial Intelligence

InterVenn is decoding the glycoproteome using powerful analytics, and AI-powered software.

InterVenn’s unique, powerful liquid biopsy platform is available today.

Our solutions are suitable for a variety of studies – untargeted (discovery) and targeted (quantification), other proof-of-concept initiatives and biomarker development. Together and with a single-blood draw, we can revolutionize disease insights into opportunities for patients. Today.
InterVenn is a private stage company focused on interrogation of the glycoproteome: a unique, and orthogonal -omics field that can be leveraged to develop clinical insights, biomarkers, diagnostics and therapeutics across multiple disease states.
InterVenn © 2021. All Rights Reserved

Join Us

joinus@venn.bio

PARTNER WITH US

partnerships@venn.bio

CONTACT US

info@venn.bio

Sitemap

Partnerships
Product Pipeline
Enabling Technologies
About
Contact

Quality Policy
Privacy Policy
Careers
Press
Events
Blog

© studioelcid